August 31, 2021 9:57 AM 27 seconds read

ANI Pharma's Purified Cortrophin Gel Application Under FDA Review

by Vandana Singh Benzinga Editor
Follow
Comments
  • The FDA has accepted ANI Pharmaceuticals Inc's ANIP supplemental marketing application for Purified Cortrophin Gel.
  • The application seeks approval for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
  • Prescription Drug User Fee Act's target action date is October 29.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: ANIP shares are 11.20% at $30.46 during the premarket session on the last check Tuesday.
ANIP Logo
ANIPANI Pharmaceuticals Inc
$64.301.64%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum71.17
Growth15.99
Quality-
Value26.17
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechLong IdeasNewsHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved